Analysts Set Medpace Holdings, Inc. (NASDAQ:MEDP) Target Price at $595.20

Shares of Medpace Holdings, Inc. (NASDAQ:MEDP) have been assigned an average recommendation of “Hold” from the twelve brokerages that are presently covering the company, Marketbeat.com reports. Nine research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $595.20.

Several analysts recently commented on MEDP shares. Leerink Partners set a $620.00 price objective on shares of Medpace in a research note on Thursday, July 23rd. TD Cowen lifted their price target on shares of Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a research report on Friday, July 24th. Truist Financial lifted their price target on shares of Medpace from $462.00 to $609.00 and gave the company a “hold” rating in a research report on Friday, July 24th. Jefferies Financial Group lowered Medpace from a “buy” rating to a “hold” rating and boosted their price target for the stock from $490.00 to $515.00 in a research note on Tuesday, July 7th. Finally, Weiss Ratings upgraded Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 12th.

Medpace Stock Performance

Medpace stock opened at $583.16 on Friday. Medpace has a one year low of $373.00 and a one year high of $677.90. The business has a fifty day moving average of $578.40 and a two-hundred day moving average of $504.09. The company has a market cap of $16.28 billion, a P/E ratio of 34.18, a price-to-earnings-growth ratio of 2.62 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last issued its earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping the consensus estimate of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The company had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. During the same period in the previous year, the firm earned $3.10 EPS. The business’s revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Sell-side analysts predict that Medpace will post 17.54 EPS for the current year.

Insider Transactions at Medpace

In other news, Director Brian Carley sold 5,000 shares of Medpace stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $608.63, for a total transaction of $3,043,150.00. Following the completion of the transaction, the director owned 27,825 shares of the company’s stock, valued at $16,935,129.75. The trade was a 15.23% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO August Troendle sold 27,174 shares of Medpace stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $618.79, for a total value of $16,814,999.46. Following the transaction, the chief executive officer directly owned 561,195 shares of the company’s stock, valued at $347,261,854.05. This trade represents a 4.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 134,471 shares of company stock worth $82,151,311. Corporate insiders own 20.50% of the company’s stock.

Hedge Funds Weigh In On Medpace

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. California State Teachers Retirement System lifted its position in shares of Medpace by 53,619.6% in the second quarter. California State Teachers Retirement System now owns 13,989,649 shares of the company’s stock valued at $7,408,778,000 after acquiring an additional 13,963,607 shares in the last quarter. BlackRock Inc. acquired a new stake in shares of Medpace during the second quarter valued at $1,323,047,000. AQR Capital Management LLC increased its position in Medpace by 65.1% during the 3rd quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock worth $518,170,000 after purchasing an additional 404,226 shares in the last quarter. Madison Asset Management LLC purchased a new stake in Medpace during the 2nd quarter worth about $128,956,000. Finally, Bank of America Corp DE acquired a new position in Medpace in the 2nd quarter valued at about $116,891,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

About Medpace

Medpace Holdings, Inc is a global contract research organization (CRO) that provides outsourced clinical development services to pharmaceutical, biotechnology and medical device companies. The company supports sponsors throughout the drug and medical product development process, from early-stage planning and clinical trial design through study execution, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, data management, biostatistics, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.